Abstract | OBJECTIVES: METHODS: In a five-center, investigator-blinded, randomized trial, EpiCeram was compared to fluticasone ( Cutivate) cream in 121 patients with moderate-to-severe AD. Primary outcome measures were: 1) reduction in disease severity, assessed as SCORAD (Severity Scoring for Atopic Dermatitis) scores; 2) improvement in pruritus; and 3) improvements in sleep habits. RESULTS:
EpiCeram reduced clinical disease severity, decreased pruritus and improved sleep habits both 14 and 28 days after initiation of therapy. Although the fluticasone-treated group showed significantly greater improvement at 14 days, SCORAD, pruritus and sleep habit scores for EpiCeram did not differ significantly from the fluticasone-treated group by 28 days. CONCLUSION: The ceramide-dominant, physiological- lipid based formulation could represent an effective stand-alone or ancillary therapy for many pediatric patients with AD.
|
Authors | Jeffrey L Sugarman, Lawrence Charles Parish |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
Vol. 8
Issue 12
Pg. 1106-11
(Dec 2009)
ISSN: 1545-9616 [Print] United States |
PMID | 20027938
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Ceramides
- Fatty Acids, Nonesterified
- Cholesterol
- Fluticasone
|
Topics |
- Adolescent
- Androstadienes
(adverse effects, therapeutic use)
- Ceramides
(administration & dosage)
- Child
- Child, Preschool
- Cholesterol
(administration & dosage)
- Dermatitis, Atopic
(drug therapy)
- Fatty Acids, Nonesterified
(administration & dosage)
- Female
- Fluticasone
- Humans
- Infant
- Male
- Single-Blind Method
|